8-K filing — Sanara MedTech Inc. (SMTI)
Filed: 2026-10-16 AccNo: 0001213900-26-110053 Size: 208 KB Item 8.01: Other Events
Stocks · News reference
Trading Halt: Halt status updated at 4:25:00 PM ET: Quotation Resumption: News and Resumption Times
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
MIMEDX to Participate in Upcoming Investor Conferences
MIMEDX Group reported second quarter 2026 net sales of $64 million and reiterated its full year financial outlook. The company announced plans to acquire Sanara MedTech in a transformational combination aimed at creating a leading regenerative medicine company and expanding MIMEDX's surgical footprint across multiple surgical subspecialties.
Sanara MedTech Q2 EPS $(0.05) Misses $0.02 Estimate, Sales $28.137M Miss $28.950M Estimate
Sanara MedTech (NASDAQ:SMTI) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $0.02 by 350 percent. This is a 78.26 percent increase over losses of $(0.23) per share from the
Halper Sadeh LLC is Investigating Whether FBRX, LXFR, SMTI, MKTX are Obtaining Fair Deals for their Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential violations of federal securities laws and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether insiders are receiving substantial benefits unavailable to ordinary shareholders and whether transaction terms limit competing offers. The investigations cover Forte Biosciences' sale to argenx, Luxfer Holdings' sale to Wynnchurch Capital affiliates, Sanara MedTech's sale to MiMedx Group, and MarketAxess Holdings' sale to Intercontinental Exchange.